Summary: The Centers for Medicare & Medicaid Services modified its psoriasis treatment coverage policy, effective May 15, 2026. Here's what billing teams need to do before that date.
CMS psoriasis treatment coverage policy has been updated, and if your practice bills for dermatology, rheumatology, or any specialty managing moderate-to-severe plaque psoriasis, this change affects your reimbursement. The policy does not carry a numbered policy code in the CMS system — it's referenced simply as the CMS Treatment of Psoriasis policy. No specific CPT or HCPCS codes are listed in the released policy data, which we'll address directly below. What matters now is understanding how the updated coverage criteria, medical necessity requirements, and prior authorization thresholds will reshape your claims workflow before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Treatment of Psoriasis |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Dermatology, Rheumatology, Internal Medicine, Primary Care |
| Key Action | Audit your psoriasis claims and prior authorization workflows before May 15, 2026 |
CMS Psoriasis Treatment Coverage Criteria and Medical Necessity Requirements 2026
Psoriasis treatment billing under Medicare has always required careful documentation. This modification raises the stakes.
CMS covers psoriasis treatments when medical necessity is established — meaning the patient's condition is documented, prior treatments have been tried and failed, and the chosen therapy is appropriate for the severity and type of psoriasis. That standard hasn't changed. What changes with a policy modification like this is how strictly CMS expects you to prove it.
For moderate-to-severe plaque psoriasis, Medicare generally requires documented failure of conventional therapies before approving advanced biologics or systemic agents. This is the step-therapy logic that runs through almost every CMS biologics coverage policy. If your documentation doesn't show that pathway — topical therapies first, then phototherapy or conventional systemics, then biologics — your claim is exposed.
Prior authorization requirements are a real concern here. CMS and its Medicare Administrative Contractors have tightened prior authorization expectations for high-cost biologics used in psoriasis. Even if a treatment is covered in principle, missing or incomplete prior auth documentation is a direct path to claim denial. Get your prior authorization process locked down before the effective date of May 15, 2026.
The CMS psoriasis coverage policy also intersects with comorbidity management. Patients with psoriatic arthritis may be treated under overlapping policies — both dermatology and rheumatology-side criteria may apply. Your billing team needs to know which diagnosis codes are driving the claim and which specialty's coverage criteria govern reimbursement.
One more thing: Medicare Administrative Contractor policies vary by region. Some MACs have issued local coverage determinations that are more specific than the national CMS guidance. Check your MAC's LCD for psoriasis to see whether it adds requirements beyond what CMS publishes nationally. If you're in a multi-state practice, you may be dealing with different standards in different regions.
CMS Psoriasis Treatment Exclusions and Non-Covered Indications
Not everything billed as psoriasis treatment will clear a CMS claim.
CMS does not cover treatments it classifies as experimental or investigational for psoriasis. That category shifts over time as evidence accumulates, which is exactly why policy modifications matter. A biologic or small-molecule therapy that was covered last year may now sit in a different tier — or a therapy that was experimental may now qualify for coverage under the updated policy.
Cosmetic indications are excluded entirely. If documentation suggests the primary purpose is cosmetic improvement rather than treatment of a medically significant condition, CMS will deny the claim. This comes up more often than it should in psoriasis billing, particularly for mild cases where the clinical documentation doesn't clearly establish medical necessity.
Off-label use is another exclusion risk. CMS covers biologics for FDA-approved indications. If a biologic approved for plaque psoriasis is being used for a different psoriasis subtype — pustular psoriasis, for example — and that use isn't supported by the coverage policy, your claim will be denied. Document the specific psoriasis type in the ICD-10 diagnosis code selection and confirm the therapy is covered for that indication.
Coverage Indications at a Glance
The released policy data does not include a detailed, indication-by-indication breakdown with assigned coverage statuses. The table below reflects what is generally understood about CMS psoriasis treatment coverage based on the policy title, modification type, and standard CMS coverage policy structure. Confirm specifics against your MAC's LCD and the full published policy at the effective date.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Moderate-to-severe plaque psoriasis | Covered (when criteria met) | ICD-10: L40.0 | Step therapy required; prior auth likely |
| Psoriatic arthritis | Covered (when criteria met) | ICD-10: L40.50–L40.59 | May fall under rheumatology and dermatology criteria simultaneously |
| Mild plaque psoriasis | Covered — topical therapies only | ICD-10: L40.0 | Advanced therapies not covered without documented failure of topicals |
| Guttate psoriasis | Coverage varies by therapy | ICD-10: L40.4 | Confirm with MAC LCD |
| Pustular psoriasis | Coverage varies by therapy | ICD-10: L40.1–L40.3 | Off-label biologic use requires specific documentation |
| Erythrodermic psoriasis | Covered — medically necessary cases | ICD-10: L40.85 | Acute severity may bypass step therapy requirements |
| Experimental or investigational therapies | Not covered | N/A | Document why conventional therapies failed before requesting coverage |
| Cosmetic treatment of psoriasis | Not covered | N/A | Must establish medical necessity, not cosmetic intent |
CMS Psoriasis Treatment Billing Guidelines and Action Items 2026
The effective date is May 15, 2026. That's your deadline. Here's what to do before it.
| # | Action Item |
|---|---|
| 1 | Pull your psoriasis claims from the last 12 months and audit for step-therapy documentation. If your charts don't show documented failure of conventional therapies before biologic use, those claims are at risk under the modified policy. Fix documentation workflows now, not after you get denials. |
| 2 | Confirm your prior authorization processes are current for all psoriasis biologics and systemic agents. Check which therapies your MAC requires prior auth for under the updated coverage policy. If your front desk or PA staff are working from an old checklist, update it before May 15, 2026. |
| 3 | Check your ICD-10 diagnosis code selection for specificity. CMS expects the most specific diagnosis code available. L40.0 for plaque psoriasis is not interchangeable with L40.50 for psoriatic arthritis. Mismatched diagnosis codes are a fast path to claim denial. Train your coders on the distinction before the effective date. |
| 4 | Contact your Medicare Administrative Contractor to confirm whether a local coverage determination supplements this CMS policy. MAC LCDs sometimes add coverage criteria or exclusions beyond the national policy. If your MAC has published a psoriasis-specific LCD, your billing guidelines need to reflect both the CMS policy and the LCD. |
| 5 | Confirm that all biologics you're billing for psoriasis are being used within their FDA-approved indications. Off-label use is an exclusion risk. If a physician is prescribing a biologic for a psoriasis subtype where coverage is unclear, loop in your compliance officer before submitting claims under the modified policy. |
| 6 | Flag any claims for psoriasis treatments currently under review or appeal. A policy modification can change the criteria against which pending claims are evaluated. Talk to your billing consultant about whether claims in process need to be re-reviewed in light of the May 15, 2026 effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Psoriasis Treatment Under CMS Policy
A Note on Code Data
The CMS Treatment of Psoriasis policy data released with this modification does not include a specific list of CPT, HCPCS, or ICD-10 codes. This is not unusual for a modified CMS coverage policy — code-level detail is often published in the full policy document or through the associated MAC LCD rather than in the top-level policy record.
Do not assume that the absence of a code list means all codes are covered or that none are affected. The opposite is true — psoriasis treatment billing spans a wide range of CPT and HCPCS codes across office visits, phototherapy, biologics administered in-office, and pharmacy-side specialty drugs. Each of those has its own coverage and reimbursement rules.
What to Do Since Specific Codes Aren't Listed
Pull the full published policy from CMS directly at the effective date. Cross-reference it against your MAC's LCD for psoriasis. The relevant code families will include E&M codes for dermatology and rheumatology visits, phototherapy procedure codes, biologic injection codes (J-codes for drugs like adalimumab, secukinumab, ixekizumab, guselkumab, risankizumab, and others), and the ICD-10-CM L40.x series for psoriasis diagnoses.
Your pharmacy billing team also needs to be in the loop. Several high-cost psoriasis biologics are billed under Part B as physician-administered drugs. Others flow through Part D. The coverage policy implications differ by administration route, and your psoriasis billing workflow needs to account for both.
If you're not sure how the code-level changes apply to your specific patient mix and billing setup, talk to your compliance officer before May 15, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.